Compare Dow Inc (DOW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs TransMedics Group Inc — how do they compare? Dow Inc trades at $28.42 (market cap $20.65B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Dow Inc is far larger — about 7.5× TransMedics Group Inc's market cap, and Dow Inc pays a 4.9% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and TransMedics Group Inc for 24 Days on average.
| DOW | TMDX | |
|---|---|---|
Market Cap | $20.65B | $2.74B |
Volume | 14,126,943 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $150.42 |
52-Week Low | $20.65 | $61.99 |
Typical Hold Time | 82 Days | 24 Days |
Enterprise Value | $36.34B | $3.13B |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.59, up 2.95% today, with a bullish technical signal despite mixed indicators. The stock shows deteriorating fundamentals with negative net income margin (-3.13%) and ROE (-7.86%) in 2025, though recent quarters have beaten EPS expectations. Cash flow trends show operational challenges with declining operating cash flow from $7.5B in 2022 to $1.0B in 2025, offset by increased financing activities.
The outlook remains cautious with analyst consensus at 'Hold' (55.55%) and $34.22 price target offering 20% upside. Key risks include persistent margin pressures, high debt levels (debt-to-asset ratio 29.87% in 2025), and cyclical chemical industry exposure. The dividend yield provides some support, but fundamental improvement is needed for sustained recovery.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
